Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios we...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Petru, Edgar, Egle, Daniel, Petzer, Andreas, Balic, Marija, Pluschnig, Ursula, Sliwa, Thamer, Singer, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813714/
https://www.ncbi.nlm.nih.gov/pubmed/35089396
http://dx.doi.org/10.1007/s00508-021-01987-9
Descripción
Sumario:A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00508-021-01987-9) contains supplementary material, which is available to authorized users.

Ejemplares similares